Matthew Weston

Stock Analyst at UBS

(2.53)

# 2,247

Out of 5,124 analysts

5

Total ratings

100%

Success rate

16.66%

Average return

Main Sectors:

Healthcare Technology

Top Industries:

Drug Manufacturers - General Software - Infrastructure

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	DBX Dropbox	Assumes: Sell	$29 → $27	$27.66	-2.39%	1	Sep 18, 2025
	NVO Novo Nordisk	Downgrades: Neutral	n/a	$51.22	-	1	Aug 5, 2025
	NVS Novartis AG	Downgrades: Neutral	n/a	$138.72	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$92.51	-	2	Feb 13, 2025

Dropbox

Sep 18, 2025

Assumes: Sell

Price Target: $29 → $27

Current: $27.66

Upside: -2.39%

Novo Nordisk

Aug 5, 2025

Downgrades: Neutral

Price Target: n/a

Current: $51.22

Upside: -

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $138.72

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $92.51

Upside: -